U.S. Senate Panel to Vote on June 18 on Subpoena for Novo Nordisk Over Ozempic, Wegovy Prices

Jun 11, 2024, 03:00 PM

The U.S. Senate Health, Education, Labor, and Pensions (HELP) Committee, chaired by Senator Bernie Sanders, announced it will vote on June 18 to decide whether to subpoena Doug Langa, President of Novo Nordisk Inc. This action is prompted by the significant price disparity for weight loss drugs Ozempic and Wegovy between the U.S. and other countries. Americans are charged $969 for Ozempic, while Germans pay only $59. The committee seeks an explanation for why these drugs cost up to 10 to 15 times more in the U.S. compared to other nations. Novo Nordisk has not yet provided a satisfactory response to these inquiries. The vote will take place later this month.